Skip to main content
Top
Published in: Osteoporosis International 3/2012

01-03-2012 | Original Article

Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial

Authors: S. L. Silverman, K. Nasser, S. Nattrass, B. Drinkwater

Published in: Osteoporosis International | Issue 3/2012

Login to get access

Abstract

Summary

We examined how the use of bone turnover markers and educational information affects persistence of bisphosphonate use in osteoporotic patients. We found that reporting bone turnover results and/or educational information did not affect persistence.

Introduction

Long-term adherence and persistence to osteoporosis medication are poor. We examined whether reporting of bone turnover marker results, education about osteoporosis, or a combination of both would increase persistence to oral bisphosphonates.

Methods

Two hundred and forty women who were 5 years postmenopausal with BMD at least 2.0 standard deviations below normal were recruited for the study. All women were given a new prescription for alendronate and randomly assigned to one of four groups: (1) bone marker results at baseline, 3 and 12 months; (2) educational materials every month and a membership in the National Osteoporosis Foundation; (3) bone marker and educational information; and (4) control, no information other than usual care. Persistence among randomization groups was tested using survival analysis adjusting for the delay between intervention methods.

Results

Of those filling their initial prescription, 95.5% refilled their prescription at the end of the first month, 87% at 3 months, 82% at 6 months, and 78% at 10 months. Overall persistence through 12 months was 54%. There was no difference found among the four groups for persistence time using (p > 0.58).

Conclusion

Providing bone turnover marker results is not an effective way to enhance early compliance and persistence with drug therapy. While the women in our study felt that bone marker results and educational information were helpful to them, there was no difference in persistence between those who received either bone marker information and/or educational information and those who did not. Because of the unexpected rate of primary nonadherence, this study may be underpowered.
Literature
1.
go back to reference Silverman S, Schein JR (2001) Physician-patient decision making in osteoporosis management. J Musculoskel Med 18:124–130 Silverman S, Schein JR (2001) Physician-patient decision making in osteoporosis management. J Musculoskel Med 18:124–130
2.
go back to reference Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82(12):1493–1501PubMedCrossRef Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82(12):1493–1501PubMedCrossRef
3.
go back to reference Rubin SM, Cummings SR (1992) Results of bone density information affect women’s decisions about taking measures to prevent fractures. Ann Intern Med 116:990–995PubMed Rubin SM, Cummings SR (1992) Results of bone density information affect women’s decisions about taking measures to prevent fractures. Ann Intern Med 116:990–995PubMed
4.
go back to reference Silverman S, Drinkwater B (1997) Effect of bone density information on decision making about estrogen. Obstet Gynecol 89:321–325PubMedCrossRef Silverman S, Drinkwater B (1997) Effect of bone density information on decision making about estrogen. Obstet Gynecol 89:321–325PubMedCrossRef
5.
go back to reference Cummings SR, Palermo L, Browner W et al (2000) Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to mean. JAMA 283:1318PubMedCrossRef Cummings SR, Palermo L, Browner W et al (2000) Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to mean. JAMA 283:1318PubMedCrossRef
6.
go back to reference Papanioannou A, Parkinson W, Adachi J et al (1998) Women’s decisions about taking measures to prevent fractures. Can Med Assoc J 15(10):1253–1257 Papanioannou A, Parkinson W, Adachi J et al (1998) Women’s decisions about taking measures to prevent fractures. Can Med Assoc J 15(10):1253–1257
7.
go back to reference Gleeson T, Iversen MD, Avorn J, Brookhart AM, Katz JN, Losina E, May F, Patrick AR, Shrank WH, Solomon DH (2009) Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 20:2127–2134. doi:10.1007/s00198-009-0976-0 PubMedCrossRef Gleeson T, Iversen MD, Avorn J, Brookhart AM, Katz JN, Losina E, May F, Patrick AR, Shrank WH, Solomon DH (2009) Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 20:2127–2134. doi:10.​1007/​s00198-009-0976-0 PubMedCrossRef
8.
go back to reference Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123PubMedCrossRef Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123PubMedCrossRef
9.
go back to reference Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, Grauer A, Cahall D, Watts NB, Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:1296–1304PubMedCrossRef Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, Grauer A, Cahall D, Watts NB, Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:1296–1304PubMedCrossRef
10.
go back to reference Physician’s guide to prevention and treatment of osteoporosis (2003) National Osteoporosis Foundation; Washington D.C. Physician’s guide to prevention and treatment of osteoporosis (2003) National Osteoporosis Foundation; Washington D.C.
11.
go back to reference Fraenkel L, Gulanski B, Wittink D (2007) Patient willingness to take teriparatide. Patient Educ Couns 65(2):237–244PubMedCrossRef Fraenkel L, Gulanski B, Wittink D (2007) Patient willingness to take teriparatide. Patient Educ Couns 65(2):237–244PubMedCrossRef
12.
go back to reference Ratcliffe J, Buxton M, McGarry T, Sheldon R, Chancellor J (2004) Patients’ preferences for characteristics associated with treatments for osteoarthritis. Rheumatology 43:337–345PubMedCrossRef Ratcliffe J, Buxton M, McGarry T, Sheldon R, Chancellor J (2004) Patients’ preferences for characteristics associated with treatments for osteoarthritis. Rheumatology 43:337–345PubMedCrossRef
13.
go back to reference Potts M, Weinberger M, Brandy KD (1984) Views of patients and providers regarding the importance of various aspects of an arthritis treatment program. J Rheumatol 11:71–75PubMed Potts M, Weinberger M, Brandy KD (1984) Views of patients and providers regarding the importance of various aspects of an arthritis treatment program. J Rheumatol 11:71–75PubMed
14.
go back to reference Fraenkel L, Gulanski B, Wittink D (2006) Patient treatment preferences for osteoporosis. Arthritis Rheum 55(5):729–735PubMedCrossRef Fraenkel L, Gulanski B, Wittink D (2006) Patient treatment preferences for osteoporosis. Arthritis Rheum 55(5):729–735PubMedCrossRef
Metadata
Title
Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial
Authors
S. L. Silverman
K. Nasser
S. Nattrass
B. Drinkwater
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 3/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-011-1721-z

Other articles of this Issue 3/2012

Osteoporosis International 3/2012 Go to the issue